The K14Q paper includes human data, but those human data are not a trial of administered MOTS-c. Its mixed evidence types must remain clearly labeled. Primary report
What was reported
The investigators examined a mitochondrial variant associated with a K14Q substitution in MOTS-c. A three-cohort analysis involving 27,527 people linked the variant with diabetes prevalence in men, with an activity-related pattern in one cohort. Separate cell and mouse experiments compared the variant peptide with the reference peptide. The abstract describes sex-specific differences across the reported observations. Primary report
Our appraisal: keep each population in its own evidence column
A human genetic association, a cell-function experiment, and an animal intervention can contribute complementary information. They cannot be merged into a statement that thousands of people received a peptide and benefited. The human sample size belongs to the genetic analysis only.
Subgroup interpretation also needs formal scrutiny. A signal reported in men but not women is not automatically proof of a sex interaction; the appropriate interaction estimate and its uncertainty should be examined. Activity-based subdivisions introduce additional comparison and measurement questions.
Genetic variation can support mechanistic hypotheses, but ancestry, population structure, linked variants, and other factors need consideration before a causal account is accepted. None of those concerns is resolved merely by a large participant count.
Before release, review cohort definitions, diabetes ascertainment, activity measurement, interaction testing, and independence of replication. This report does not establish a genetic test for selecting peptide treatment.
Frequently asked questions
Did 27,527 people receive MOTS-c?
No. That count concerns the human cohort analysis.
Were administration experiments separate?
Yes. The report includes distinct preclinical experiments.
Is prevalence the same as incident disease risk?
No. They are different measures.
Does significance in one sex prove a sex interaction?
No. Direct interaction testing is needed.
Was activity relevant to a subgroup finding?
Yes, in one reported cohort analysis.
Does this establish personalized peptide treatment?
No. That clinical use was not tested.
What remains to be reviewed?
Complete genetic, subgroup, replication, and experimental methods.